Emicizumab is a medicine from the Roche laboratory indicated for the treatment of hemophilia, which may be useful to replace the current treatments. This is an experimental monoclonal antibody, which replaces factor VIII that is necessary for blood coagulation to occur correctly in hemophiliacs.
Hemophilia is a disease characterized by the difficulty or impossibility of clotting the blood, causing the person to continue bleeding continuously even with small cuts. This genetic disease is discovered in childhood and its treatment can be done with injections of 3 or 4 times a week, but Emicizumabe can reduce these injections to only 1 per week.
Indications
To reduce the risk of bleeding and control hemophilia in:
- Persons over 12 years of age with hemophilia A, with or without Factor VIII inhibitors and
- Children under 12 with Factor VIII inhibitors.
How to use
This medicine should be given as an injection once a week or according to medical advice. The administration should be made by the pharmacist, doctor or nurse.
Side effects
Clinical studies developed by Roche indicate that Emicizumab is well tolerated and only has reactions at the injection site, such as redness and mild swelling.
Price and where to buy
This medicine is under study and as it has not yet been approved by Anvisa, it can not be marketed.
